There is now increasing evidence that endothelial dysfunction is an early event in the
pathophysiology of cardiovascular diseases and can be corrected with certain therapies such as …

Peroxisome proliferator-activated receptors (PPAR) are nuclear receptors acting as transcription
factors on numerous target genes after heterodimerization with the retinoid X receptor. …

Macitentan, also called Actelion-1 or ACT-064992 [N-[5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)-pyrimidin-4-yl]-N′-propylaminosulfonamide],
is a new dual ET A /ET …

Background— Endothelin (ET)-1 is a potent vasoconstrictor that contributes to vascular
remodeling in hypertension and other cardiovascular diseases. Endogenous ET-1 is produced …

ET (endothelin)-1 was first described as a potent vasoconstrictor. Since then, many other
deleterious properties mediated via its two receptors, ET A and ET B , have been described, …

Starting from the structure of bosentan (1), we embarked on a medicinal chemistry program
aiming at the identification of novel potent dual endothelin receptor antagonists with high oral …

Objective— Peroxisome proliferator–activated receptors (PPARs) may modulate in vitro the
vascular production of vasoactive peptides such as endothelin-1 (ET-1). Thus, we …

Background: The aim of this study was to investigate the involvement of angiotensin II and
oxidative stress on cardiovascular damage induced by chronic subcutaneous aldosterone …

… A total of 250 ng of random hexamer and 0.5 mm deoxynucleotide triphosphate were
added to total RNA (0.5–1 μg) in 12 μl before heating at 65 C for 5 min. Then a cocktail of 1× …

… M. Iglarz is supported by a fellowship from Fondation pour la Recherche Médicale of France.
The authors are grateful to Dr Ping Yue, Manon Laprise, André Turgeon, Suzanne Diébold, …